HK1246292A1 - 1，3，5-三嗪衍生物及其使用方法 - Google Patents

1，3，5-三嗪衍生物及其使用方法 Download PDF

Info

Publication number
HK1246292A1
HK1246292A1 HK18105822.3A HK18105822A HK1246292A1 HK 1246292 A1 HK1246292 A1 HK 1246292A1 HK 18105822 A HK18105822 A HK 18105822A HK 1246292 A1 HK1246292 A1 HK 1246292A1
Authority
HK
Hong Kong
Prior art keywords
alkyl
naphthenic base
compound
pharmaceutically acceptable
idh2
Prior art date
Application number
HK18105822.3A
Other languages
English (en)
Other versions
HK1246292B (zh
Inventor
赵娜
趙娜
王树龙
刘希杰
王樹龍
胡远东
张慧
劉希傑
罗鸿
彭勇
胡遠東
韩永信
张喜全
張慧
徐宏江
羅鴻
韓永信
張喜全
Original Assignee
正大天晴药业集团股份有限公司
连云港润衆制药有限公司
北京赛林泰医药技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 正大天晴药业集团股份有限公司, 连云港润衆制药有限公司, 北京赛林泰医药技术有限公司 filed Critical 正大天晴药业集团股份有限公司
Publication of HK1246292A1 publication Critical patent/HK1246292A1/zh
Publication of HK1246292B publication Critical patent/HK1246292B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

一种通式Ⅰ和通式Ⅱ的化合物或其药学上可接受的盐或水合物、其制备方法及其药物组合物。所述通式Ⅰ和通式Ⅱ的化合物具有异柠檬酸脱氢酶2（IDH2）抑制活性，能治疗IDH2突变诱发的癌症。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
HK18105822.3A 2015-07-30 2016-07-29 1,3,5-三嗪衍生物及其使用方法 HK1246292B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510459126 2015-07-30
CN201510459126.X 2015-07-30
PCT/CN2016/092254 WO2017016513A1 (zh) 2015-07-30 2016-07-29 1,3,5-三嗪衍生物及其使用方法

Publications (2)

Publication Number Publication Date
HK1246292A1 true HK1246292A1 (zh) 2018-09-07
HK1246292B HK1246292B (zh) 2022-03-11

Family

ID=

Also Published As

Publication number Publication date
RU2018105614A3 (zh) 2019-11-20
US20190062308A1 (en) 2019-02-28
KR20180031036A (ko) 2018-03-27
JP6786086B2 (ja) 2020-11-18
JP2018521104A (ja) 2018-08-02
EP3330258A1 (en) 2018-06-06
US10745383B2 (en) 2020-08-18
TW201704224A (zh) 2017-02-01
AU2016299092B2 (en) 2020-08-20
CA2993687A1 (en) 2017-02-02
DK3330258T3 (da) 2021-08-16
CA2993687C (en) 2023-09-26
EP3330258B1 (en) 2021-07-14
WO2017016513A1 (zh) 2017-02-02
KR102303011B1 (ko) 2021-09-16
BR112018001780A2 (zh) 2018-09-11
ES2881695T3 (es) 2021-11-30
EP3330258A4 (en) 2019-01-02
HUE056537T2 (hu) 2022-02-28
PT3330258T (pt) 2021-08-19
RU2724333C2 (ru) 2020-06-23
CN113307794A (zh) 2021-08-27
TWI722004B (zh) 2021-03-21
CN107922358A (zh) 2018-04-17
ZA201801301B (en) 2020-07-29
CN107922358B (zh) 2021-05-07
AU2016299092A1 (en) 2018-02-22
RU2018105614A (ru) 2019-08-29

Similar Documents

Publication Publication Date Title
TWI722004B (zh) 1,3,5-三嗪衍生物及其使用方法
TWI772291B (zh) 取代的吡咯並嘧啶類ｃｄｋ抑制劑、包含其藥物組合物及其用途
CA2925889C (en) Hydrochloride salt form for ezh2 inhibition
WO2021238827A1 (zh) Egfr抑制剂、其制备方法及用途
TW201619133A (zh) 新穎亞氨腈（ｉｍｉｎｏｎｉｔｒｉｌｅ）衍生物
CN109071471A (zh) 内磺酰胺化合物及其使用方法
CN115873018A (zh) 苯并嘧啶和苯并三嗪类造血祖细胞激酶1降解剂及其应用
US10253017B2 (en) Derivatives of 2-aminopyridine as adenosine A2B receptor antagonists and ligands of the melatonin MT3 receptors
WO2010057418A1 (zh) 苯氧基嘧啶衍生物及其制备方法和用途
JPH037257A (ja) ピリジン誘導体及びそれを有効成分とする向精神剤
US20170029404A1 (en) Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition
CN107922375A (zh) 靶向idh2突变的抗肿瘤化合物及其使用方法
IE901242L (en) Heteroarylmethoxy phenylalkanol derivatives
CN113248474A (zh) 五元氮唑杂环衍生物及其制备方法和用途
JP6889186B2 (ja) 疼痛を治療するための重水素化合物
KR20110074574A (ko) 1-부틸-2-히드록시아르알킬 피페라진 유도체 및 항-우울증제로서의 그 용도
JP2009535374A (ja) ピリジルメチルピペラジンおよび−ピペリジン誘導体のｎ−オキサイド
US20160022675A1 (en) Processes for preparing tetrahydroisoquinolines
BR112019001510B1 (pt) Composto, e, uso de um composto para manufatura de um medicamento para tratar profilática ou terapeuticamente fibrose pulmonar, ou uma enfermidade relacionada em um indivíduo com fibrose pulmonar ou em risco de desenvolver fibrose pulmonar
JP7175878B2 (ja) 新規ベンズイミダゾロン化合物およびその医薬用途
JP2015124211A (ja) キナゾリノン誘導体
KR20210151849A (ko) 퀴놀린 유도체 및 암의 치료를 위한 그의 용도
TWI313602B (en) Gyrase inhibitors and uses thereof
HK1246292B (zh) 1,3,5-三嗪衍生物及其使用方法
WO2021070957A1 (ja) ベンゼン縮合環化合物、およびそれを含有する医薬組成物